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Background: The risk of brain swelling after dural opening is high in patients with midline shift undergoing
supratentorial tumor surgery. Brain swelling may result in increased intracranial pressure, impeded tumor exposure,
and adverse outcomes. Mannitol is recommended as a first-line dehydration treatment to reduce brain edema and
enable brain relaxation during neurosurgery. Research has indicated that mannitol enhanced brain relaxation in
patients undergoing supratentorial tumor surgery; however, these results need further confirmation, and the optimal
mannitol dose has not yet been established. We propose to examine whether different doses of 20% mannitol improve
brain relaxation in a dose-dependent manner when administered at the time of incision. We will examine patients with
preexisting mass effects and midline shift undergoing elective supratentorial brain tumor surgery.
Methods: This is a single-center, randomized controlled, parallel group trial that will be carried out at Beijing Tiantan
Hospital, Capital Medical University. Randomization will be achieved using a computer-generated table. The study
will include 220 patients undergoing supratentorial tumor surgery whose preoperative computed tomography/magnetic
resonance imaging results indicate a brain midline shift. Patients in group A, group B, and group C will receive
dehydration treatment at incision with 20% mannitol solutions of 0.7, 1.0, and 1.4 g/kg, respectively, at a rate of
600 mL/h. The patients in the control group will not receive mannitol. The primary outcome is an improvement
in intraoperative brain relaxation and dura tension after dehydration with mannitol. Secondary outcomes are
postoperative outcomes and the incidence of mannitol side effects.
Discussion: The aim of this study is to determine the optimal dose of 20% mannitol for intraoperative infusion.
We will examine brain relaxation and outcome in patients undergoing supratentorial tumor surgery. If our results
are positive, the study will indicate the optimal dose of mannitol to improve brain relaxation and avoid side
effects during brain tumor surgery.
Trial registration: The study is registered with the registry website http://www.chictr.org with the registration
number ChiCTRTRC13003984 (17 December 2013).
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The average incidence of intracranial tumors in China is
ten per hundred thousand healthy people. Most of these
tumors are supratentorial tumors (79%), the most com-
mon of which are gliomas, meningiomas, and pituitary
tumors. Supratentorial tumors produce significant mass
effects in the brain, and certain types are accompanied
by significant peritumoral edema that leads to increased
intracranial pressure. Bedford et al. [1] showed that the
preoperative degree of peritumoral edema was closely
related to the postoperative increase in intracranial pres-
sure. Rasmussen et al. [2] revealed that the risk of brain
swelling after dura opening was very high in 692 cases of
patients with glioma with midline shift undergoing crani-
otomy; this result indicated that in cases with preoperative
increased intracranial pressure, dehydration treatment
should be administered before cutting the dura. Dehy-
dration aids in ensuring proper brain relaxation and facili-
tates tumor exposure.
Higher osmotic pressure in the blood vessels after the in-
fusion of mannitol drives water molecules from the brain
tissue to blood vessels and results in brain tissue dehydra-
tion. However, the role of mannitol in reducing brain
edema depends on an intact blood–brain barrier (BBB). If
the BBB is damaged, mannitol will extravasate outside the
blood vessels and will transfer water molecules into brain
tissue, which will aggravate cerebral edema and increase
intracranial pressure [3]. There may be some degree of
BBB disruption in certain patients, which would prevent
the desirable effects of mannitol; however, the extent of this
disruption is unclear and often affected by multiple-dose
mannitol [4]. The use of mannitol for the type of surgery
that patients in our study will undergo has been found
overall to be beneficial; however, the appropriate dose of
mannitol is controversial, particularly since large multiple
doses can have negative effects. The point of our study is
to determine a dose that leads to a beneficial effect without
triggering negative effects. Some clinicians [5,6] advocate
high doses (>1.0 g/kg) of mannitol to effectively reduce
intracranial pressure, while others recommend lower doses
(<1.0 g/kg) [7,8]. Treatment guidelines for using mannitol
in patients with traumatic brain injury and stroke have
been published and provide recommendations regarding
the dose and timing of mannitol. However, there is still
controversy concerning dehydration treatment with man-
nitol in patients with preoperatively increased intracranial
pressure during brain tumor surgery.
The effect of mannitol on intraoperative brain relaxation
has been increasingly studied in recent years. In 2007,
Rozet et al. [9] compared the effects of mannitol and
hypertonic saline on intraoperative brain relaxation in 40
patients undergoing elective craniotomy and found a simi-
lar effect in both treatment groups. However, the intrace-
rebral pathology of the patients in this study varied widely,and only six of the ten patients with supratentorial brain
tumors received mannitol. Additionally, the preoperative
peritumoral edema and intracranial pressure were not re-
corded, and only a single dose of mannitol (1 g/kg) was
administered. Wu et al. [10] compared the effects of
160 mL of 3% hypertonic saline and 150 mL of 20% man-
nitol on brain relaxation. Their study suggested that 3%
hypertonic saline provided better relaxation; however, the
lengths of hospital and intensive care unit stays did not
significantly differ. The dose of mannitol administered in
the study was not adjusted according to the preoperative
intracranial pressure, the intracranial mass occupying ef-
fect, or the body weight of the patient. Furthermore, the
dose of mannitol was lower than the commonly used clin-
ical dose. Therefore, this study is of little use as a clinical
guide. More recently, a prospective randomized controlled
study [11] demonstrated that a single dose of 0.7 or
1.4 g/kg mannitol achieved similar brain relaxation in
patients undergoing craniotomy and tumor resection.
However, further statistical analysis that took into ac-
count the preoperative midline shift indicated that the
high dose yielded a better outcome. The study indicated
that the effect of mannitol on brain relaxation may be
dose-dependent if the preoperative increase in intra-
cranial pressure is taken into consideration; however,
further study is required to verify this suggestion.
Mannitol and hypertonic saline are often used as dehy-
drating agents in neurosurgery and neurology. Hyper-
tonic saline has been widely used in patients with stroke
and traumatic brain injury to reduce brain edema and
intracranial pressure; however, its use, especially during
the operation, remains controversial in patients under-
going brain tumor surgery. Starke et al. [12] presented a
comprehensive assessment of the effect of hypertonic sa-
line during brain tumor resection and did not recom-
mend it as a treatment for dehydration in brain tumor
surgery unless the patient presents with hyponatremia
and hypotension. Dehydration treatment with mannitol
was recommended to reduce brain edema and provide
brain relaxation during neurosurgery.
The above series of randomized control trials aimed to
assess the effect of mannitol on brain edema and relax-
ation; however, there were limitations associated with their
conclusions. First, the studies did not describe preopera-
tive factors that may affect brain relaxation, such as the
size and histological type of the tumor, peritumoral edema
[2], the position of the head and body, body temperature,
and arterial carbon dioxide partial pressure. Second, the
studies did not indicate whether high-risk patients with
increased brain pressure were included. Finally, these
studies lacked data comparing the clinical side effects
and patient outcomes following the infusion of mannitol.
Based on the current literature, we propose that diffe-
rent doses of mannitol will improve brain relaxation, as
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for patients with preoperative midline shift undergoing
elective supratentorial brain tumor surgery. A double-blind
randomized controlled trial of intraoperative intravenous
mannitol in patients undergoing supratentorial tumor sur-




The primary aim of our trial is to investigate whether the
intraoperative administration of 0.7, 1.0, and 1.4 g/kg body
weight intravenous mannitol at a rate of 600 mL/h results
in an improvement of brain relaxation in patients with a
supratentorial brain tumor. Brain relaxation will be scored
by the surgeon, who is blinded to the treatment, upon
opening the dura using a four-point scale: 1 = completely
relaxed, 2 = satisfactorily relaxed, 3 = firm brain, 4 = bul-
ging brain [13].
Secondary aim
The secondary aim is to determine whether different
doses of intraoperative mannitol alter hemodynamic pa-
rameters, plasma electrolytes, blood glucose, and lactic
acid such that the perioperative outcomes of patients are
improved. Additionally, we want to determine whether
different doses of intraoperative mannitol alter patients’
three-month postoperative outcomes, including cerebral
edema, cerebral hemorrhage, recurrence, and death.
Anesthesia depth measurement
We will measure the mean blood pressure, heart rate, bis-
pectral index, end-tidal carbon dioxide, and inspiratory and
expiratory gas concentrations and will maintain a similar
anesthesia depth. The mean arterial pressure will be main-
tained between 10% below and 20% above the baseline
value. Anesthetic depth will be determined by using the bis-
pectral index (Covidien LLC, USA), which will be main-
tained between 40 and 60.
Study design
This is a prospective, single-center, randomized, paral-
lel group controlled trial that is being conducted at
Beijing Tiantan Hospital, Capital Medical University,
Beijing, China. Study recruitment commenced on 1
January 2014. Recruitment is expected to take 12 months.
There are more than 1,000 cases of supratentorial tumor
surgery per year at Beijing Tiantan Hospital, Capital
Medical University. We plan to complete the study in
one year.
Randomization and blinding
Randomization will be conducted via a computer-
produced randomized controlled table. Participants willbe randomized within 24 hours prior to surgery. A re-
search nurse will give the participants mannitol or no
drug in a black box according to the randomized con-
trolled table. The research nurse will be the only person
who is not blinded; the research team that collects and
analyzes the data, the neurosurgeon who assesses brain
relaxation, and the anesthesiologist who administers the
anesthesia will be blinded.
Selection and withdrawal of participants
Recruitment
Participants are identified by their presence on surgical lists
and are recruited from the tumor wards. The investigator
informs the participant or the participant’s nominated
representative of all aspects pertaining to participation
in the study.
The study intervention will be completed immediately
after the surgery, but follow-up visits will extend for
three months following surgery. The medical notes will
be reviewed following hospital discharge for in-hospital
complications and medication use.
Inclusion criteria
Patients scheduled to receive elective supratentorial
tumor resection at Beijing Tiantan Hospital, Capital
Medical University who are older than 18 and younger
than 60 years will be included if their preoperative im-
aging (computed tomography or magnetic resonance im-
aging) shows a midline brain shift.
Exclusion criteria
Patients will be excluded if their American Society of
Anesthesiologists physical status score is III or higher
or if their Glasgow Coma Scale score is <13. Patients
will be excluded if their plasma sodium is <130 mEq/L
or >150 mEq/L. Patients will be excluded if they have renal
insufficiency or if their creatinine clearance is <30 mL/kg.
Patients will also be excluded if they have heart disease or
if their cardiac ejection fraction is <20%.
Informed consent
Written informed consent will be obtained one day before
surgery. The capacity for providing informed consent will
be assessed routinely by the neurosurgery team, who will
decide whether the patient is suitable for inclusion in the
study. A member of the research team will also perform an
additional assessment of the participant’s ability to provide
consent one day prior to starting the study. If either the
neurosurgery or research team determines that the patient
is unable to give informed consent, the patient’s entrusted
agent will be asked to give written informed consent. If
either the patient or his entrusted agent declines consent,
then the patient will not be entered into the study. Only pa-
tients who give informed written consent will be included
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obtaining informed consent in accordance with good clin-
ical practice.
Ethics committee and regulatory approval
The trial will be conducted in accordance with the eth-
ical principles outlined in the Declaration of Helsinki,
1996 [14]; National Ethics Review for Biomedical Re-
search Involving Humans (Trial), 2007 [15]; and Inter-
national Ethical Guidelines for Biomedical Research
Involving Human Subjects, 2002 [16]. Approval was ob-
tained from the China Ethics Committee of Registering




Patients allocated to the investigational medical product
group will receive 20% mannitol at doses of 0.7, 1.0, or
1.4 g/kg at the onset of surgical incision. The drug will
be administered intravenously at a rate of 600 mL/h.
The dose and timing of administration of intravenous
mannitol will be similar to those described by Quentin
et al. [11].
Concomitant treatments
Peritumoral brain edema will be evaluated via a magnetic
resonance imaging (MRI) scan read by an experienced
radiologist and graded using the Steinhoff classification: 0-
no signs of edema, I-peritumoral brain edema limited to
2 cm, II-peritumoral brain edema limited to half of the
hemisphere, or III-peritumoral brain edema in more than
half of the hemisphere [17].
Peripheral venous access will be established upon the
patient’s arrival in the operating room. Routine monitoring
and data collection will include noninvasive blood pres-
sure, electrocardiograph, pulse oxygen saturation, end-tidal
carbon dioxide pressure, exhaled anesthetic concentration,
bispectral index, temperature, and urine output. All pa-
tients will be premedicated with midazolam (0.05 mg/kg)
intravenously 15 min prior to anesthesia induction.
Anesthesia will be induced with sufentanil (0.2 to
0.3 μg/kg), propofol (target-controlled infusion with an
initial plasma concentration of 4 μg/mL), and rocuronium
(0.6 mg/kg). After tracheal intubation, mechanical ventila-
tion will be performed with the following parameters: tidal
volume, 8 to 10 mL/kg; respiratory rate, 12 to 15/min; I: E,
1:2; inhaled oxygen fraction, 60%; and flow rate of fresh gas,
1 to 2 L/min to maintain normocapnia. Anesthesia will be
maintained with propofol (target-controlled infusion with a
plasma concentration of 3 to 5 μg/mL) and remifentanil
(0.1 to 0.2 μg/kg/min) supplemented with rocuronium for
muscle relaxation. Sufentanil will be injected to attenuate
the potent stress responses induced by noxious stimuli atcertain time points, such as scalp incision and skull drilling.
Crystalloid infusion and/or colloid will be infused as needed
to treat intravascular volume depletion. Fluid input and
output will be monitored closely.
Standard care
Standard care will be identical in both groups; only the
administration of mannitol will differ.
Cost analysis
Data on the cost of treatment will include standardized
costs for physiotherapy, neurosurgery, anesthesia, and
postoperative care. Data will be presented in terms of
total non-operative costs, costs per day, and excess costs
attributable to the treatment group.
Laboratory analyses
Blood will be sampled from a peripheral artery prior to the
initial administration and 30, 60, 120, and 180 min after the
infusion of mannitol to measure the plasma concentration
of electrolytes, osmolality, lactic acid, and glucose.
Statistics
The SPSS 19.0 software package for Windows (SPSS, Inc.,
Chicago, IL) will be used for all statistical analyses. The
primary outcome measure (difference in brain relaxation
between groups) in the full analysis will be analyzed using
the chi-squared test or Fisher’s exact test. The comparison
of continuous variables between groups will be accom-
plished using a one-way analysis of variance. Any peri-
operative factors that differ between groups will be tested
together with the treatment factor (the administration of
mannitol or placebo) via multivariate logistic regression
analysis against the brain relaxation of the patients to as-
sess their effects on brain relaxation. A significance level
of P <0.05 will be chosen for all tests.
Sample size and justification
We used the PASS 2008 software (NCSS LLC, USA) for
Windows to calculate the sample size. According to the
data of incidence of satisfactory brain relaxation in
Quentin’s research [11], a sample size of 194 achieves
85% power to detect a significance level (alpha) of 0.05
(Figure 1) using a chi-squared test with nine degrees of
freedom [18]. Degree of freedom is the chi-squared distri-
bution. Alpha is the probability of rejecting a true null hy-
pothesis. We propose to study 220 patients, with 55
participants in each group. Twenty-six additional patients
are included to account for dropouts during the follow-up
visits within three months after the brain tumor surgery.
Reporting of adverse events
All adverse events will be recorded and closely moni-

















0.80 0.85 0.90 0.95
Figure 1 Sample size calculation. Power is the probability of
rejecting a false null hypothesis; this item should be close to one.
N is the size of the sample drawn from the population.
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event. Participants will be asked to contact the study site
immediately in the case of any serious adverse events.
The chief investigator will be informed immediately of
any serious adverse events and will determine (in co-
operation with the treating medical practitioners) the
seriousness and causality of these events.
All treatment-related serious adverse events will be re-
corded and reported to the research ethics committee as
part of the annual reports. Unexpected serious adverse
events will be reported to the research ethics committee
within the relevant time frames. The chief investigator
will be responsible for all adverse event reporting.
Potential conflicts of interest
The manufacturer of mannitol has no involvement in
the design or funding of this study. All drugs are being
prescribed from the central pharmacy in Beijing Tiantan
Hospital at normal prices. There will be no potential con-
flicts of interest.
Discussion
Mannitol is often recommended as the first-choice hyper-
osmotic drug to treat increased intracranial pressure (ICP)
and alleviate brain bulk during intracranial surgery [19].
However, the optimal administration and dosage of man-
nitol for brain relaxation remain controversial, especially
in patients with preoperative increased ICP. A common
routine dose is frequently chosen for a given surgical pro-
cedure regardless of the size of the lesion and the mass ef-
fect that results.
Previous prospective randomized trials have focused
on the relationship between mannitol and intraoperative
brain relaxation; however, none of these trials examined
how different doses of mannitol influenced brain relax-
ation in patients with a preoperative brain midline shift.Rozet et al. [9] observed the effect of a single mannitol
dose on brain relaxation in patients with widely varying
intracerebral pathologies, including supratentorial tumor.
Quentin et al. [11] examined the effects of two doses (0.7
and 1.4 g/kg) of mannitol on brain relaxation in tumor
patients, neither of which was the routine clinical dose
(1 g/kg); additionally, they did not consider the effect of
preoperative intracranial mass. However, these studies
indicated that the effect of mannitol on brain relaxation
was dose-dependent. The current proposal is a pro-
spective randomized controlled study that aims to
examine the effects of three doses of mannitol on brain
relaxation in patients with preoperative midline shift.
Patients with large brain lesions have often received re-
peated mannitol doses to prevent brain herniation; how-
ever, the repeated intraoperative use of large doses of
mannitol may precipitate serious side effects. The main side
effects of mannitol include electrolyte abnormalities (for ex-
ample, hypokalemia) and renal and cardiac dysfunction. Pa-
tients with heart failure, pulmonary edema, electrolyte
imbalance, chronic hypertension, coronary heart disease,
and diabetes often have renal dysfunction without clinical
manifestations. Mannitol can exacerbate this dysfunction
and lead to kidney injury [20,21]. Cardiac preload and cen-
tral venous pressure increase 5 to 15 min after mannitol is
administered [22]. The diuretic effects of mannitol may
cause water and electrolyte imbalances, hypotension, and
decreased plasma concentrations of sodium, potassium,
and chlorine [23]. As shown in other studies [24,25], in-
creased doses of mannitol resulted in an increase in osmo-
larity, a decrease in serum sodium concentration, and an
increase in urine output. The development of hyponatremia
can be explained by the changes in osmolarity and the ini-
tial volume shift toward the intravascular compartment
along the osmolar gradient and the resulting hemodilution.
Higher doses of mannitol result in a dose-related increase
in osmolarity, as well as a similar dose-related decrease in
brain water content; this results in better relaxation scores
in patients with traumatic brain injury [26]. Manninen et al.
[23] described a significant increase in the serum potassium
level, which reached a maximum mean increase of
1.5 mmol/L, after high-dose mannitol (2 g/kg) adminis-
tration in seven patients undergoing cerebral aneurysm
clipping. Therefore, patients should be closely and care-
fully observed for side effects, especially patients who
receive a large dose of mannitol and/or have preopera-
tive increased intracranial pressure.
During the operation, the neurosurgeon will decide
whether to initiate treatment for brain bulk via the assess-
ment of intraoperative brain relaxation, which is not an ob-
jective sign, such as intracranial pressure. Treatments for
improving brain relaxation include adjusting the ventilator
to induce hyperventilation, expanding the surgical incision
site, and infusing mannitol; these procedures contribute to
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ment of the degree of brain relaxation can be used as a
diagnostic criterion prior to treatment. Monitoring intra-
cranial pressure or cerebral water content is not routine
during brain tumor resection because the extra invasive
monitoring of patients increases the risk of brain hernia-
tion. Sorani et al. [8] performed a retrospective study to
characterize the dose–response relationship between man-
nitol and ICP in intensive care unit patients with traumatic
brain injury and found that the degree and incidence of
peritumoral edema greatly varied. Therefore, it is not ap-
propriate to measure the effect of mannitol in patients with
supratentorial tumors, including gliomas and meningiomas,
using brain water content.
In this prospective randomized trial, we will observe the
effects of different doses of mannitol on patient outcomes
three months postoperatively. Patients undergoing crani-
otomy commonly have complications that include postop-
erative cerebral edema, cerebral hemorrhage, recurrence,
and even death, which are closely related to intraoperative
tumor exposure, resection, and sufficient coagulation. The
incidence of postoperative complications determines the
length of intensive care unit and hospital stay, as well as
patient outcome. Mannitol may help improve tumor ex-
posure and resection. However, if the BBB is damaged,
mannitol will be transferred from the ruptured or highly
permeable blood vessels into brain tissue, which reverses
the osmotic pressure difference and results in brain
edema. Animal studies [26] demonstrate that five repeated
doses of mannitol lowered ICP and reduced cerebral
edema; however, edema increased following greater expos-
ure to mannitol.
Trial status
The study was also registered with the registry website
http://www.chictr.org with the registration number
ChiCTRTRC13003984 (17 December 2013). The study
began on 2 January 2014, and the planned completion
date is 1 April 2015.
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